A PHASE 2, OPEN LABEL, MULTICENTER STUDY OF ALN-CC5 ADMINISTERED SUBCUTANEOUSLY IN ADULT

Registry ID

ALN-CC5-004

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ALNYLAM PHARMACEUTICALS INC

Start date

2018-09-13

Completion date

2019-05-24

Last update

2017-10-26

Conditions

• ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Related clinical trials

• A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
• A PHASE 3, OPEN-LABEL MULTICENTER STUDY OF ALXN1210 IN CHILDREN AND ADOLESCENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
• SINGLE ARM STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAIVE ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

View on source registry